References
- Ward N. The impact of intestinal failure on oral drug absorption: a review. J Gastrointest Surg. 2010;14(6):1045–51.
- Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm. 2011;68(23):2241–7.
- Kamimura M, Watanabe K, Kobayakawa M, Mihara F, Edamoto Y, Teruya K, et al. Successful absorption of antiretroviral drugs after gastrojejunal bypass surgery following failure of therapy through a jejunal tube. Intern Med. 2009;48(12):1103–4.
- Boffito M, Lucchini A, Maiello A, Dal Conte I, Hoggard PG, Back DJ. Lopinavir/ritonavir absorption in a gastrectomized patient. AIDS. 2003;17(1):136–7.
- Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65(24):2347–57.
- DeJesus E, Lalezari JP, Osiyemi OO, Raune PJ, Ryan R, Kakuda TN, et al. Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults. Antivir Ther. 2010;15(5):711–20.
- Piñeiro Corrales G, Olivera Fernández R, Guindel Jiménez C; Grupo de Nutrición SEFH/SENPE. Drug administration in patients with enteral tube nutrition. Nutr Hosp. 2006;21(Suppl 4):1–216.
- Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet. 1999;36(3):233–54.
- Chiu YL, Klein CE, Woodward WC, King KR, Naylor C, Awni W, et al. Lack of effect of gastric acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir in HIV-infected patients. AIDS Patient Care STDS. 2007;21(4):247–51.
- Overton ET, Tschampa JM, Klebert M, Royal M, Rodriguez M, Spitz T, et al. The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy. J Clin Pharmacol. 2010;50(9):1050–5.
- Kaplan SS, Hicks CB. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother. 2005;6(9):1573–85.
- Scholler-Gyure M, Boffito M, Pozniak AL, Leemans R, Kakuda TN, Woodfall B, et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy. 2008;28(10):1215–22.
- Macha S, Yong CL, MacGregor TR, Castles M, Quinson AM, Rouyrre N, et al. Assessment of nevirapine bioavailability from targeted sites in the human gastrointestinal tract. J Clin Pharmacol. 2009;49(12):1417–25.
- Kumar PN, Patel P. Lamivudine for the treatment of HIV. Expert Opin Drug Metab Toxicol. 2010;6(1):105–14.
- Liu X, Ma Q, Zhang FJ. Therapeutic drug monitoring in highly active antiretroviral therapy. Expert Opin Drug Saf. 2010;9(5):743–58.